Dingrui Biomed

Dingrui Biomed is a China-based biopharmaceutical company specializing in the discovery and development of next-generation targeted protein degradation (TPD) therapies. The company leverages its proprietary Glue-Tide platform to systematically identify and optimize molecular glue degraders, which offer advantages over traditional PROTACs in terms of drug-like properties and the ability to target 'undruggable' proteins. Dingrui focuses on high-value targets in oncology and immunology, aiming to provide breakthrough treatments for patients with significant unmet medical needs. Its research facilities are strategically located in Suzhou and Beijing's life science hubs.